Events

UK Bioscience Forum w/ Gareth Jones & Peju Oshisanya

Intellectual Property in AI and data technologies

11:45am | 14 October 2020

The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector?

Speakers:

  • Gareth Jones, VP Intellectual Property at BenevolentAI
  • Dr Nicola Baker-Munton, Chief Executive Officer at Statagem
  • Joe Foster, COO at Mogrify
  • Tim Hoctor, Vice President of Global Professional Services at Elsevier
  • Jule Sigall, Associate General Counsel, Open Innovation, IP Group at Microsoft

→ Register here

Diversity in data for drug discovery and clinical applications

11:45am | 14 October 2020

A lack of diversity in clinical datasets is a known problem for the life sciences industry, and one that must be addressed. In this session, we will discuss what different organisations are doing to address this, and share lessons they have learned from their experiences.

Speakers:

  • Peju Oshisanya MSc, BSc (HONS), Director, Clinical Programme Leader at BenevolentAI
  • Maria Chatzou Dunford, CEO and Co-Founder at Lifebit Biotech
  • Annette Jack, Founder at Egality
  • Dr Jason Mellad, CEO at Start Codon
  • Umang Patel, Clinical Director, Babylon

→ Register here


Peju Oshisanya

Clinical Drug Development Leader & Data Diversity Advocate at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Gareth Jones

VP Intellectual Property

Gareth Jones is one of the the world's leading intellectual property strategists (IAM Strategy 300). At BenevolentAI he is responsible for IP activities including strategy, portfolio development, competitive intelligence, fundraising and M&A diligence, patent and data licensing, and collaborations. Gareth has worked at IBM, Vodafone, Microsoft, and also at tech startup SwiftKey where he built and scaled IP operations for one of the largest UK tech exits of 2015/2016


More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022